Troy– Author –
-
Arvinas Secures IND Clearance for Oral LRRK2 Degrader ARV-102, Expanding Neurodegenerative Pipeline and Partnering with Michael J. Fox Foundation
Arvinas Press Release / MarketBeat / GLOBE NEWSWIRE USA Overview Arvinas announced FDA approval of its Investigational New Drug (IND) application for ARV-102, an oral PROTAC protein degrader designed for specific neurodegenerative diseas... -
Daiichi Sankyo and AstraZeneca’s Gastric Cancer ADC Receives Positive EMA CHMP Opinion for Approval
European Medicines Agency (EMA) Europe Overview The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval for an antibody-drug conjugate (ADC) develo... -
Novel LNP Formulation Significantly Enhances Extra-hepatic mRNA Delivery to Lung Tissue, Published in Nature Communications
Nature Communications Unknown Overview A groundbreaking study in Nature Communications reports a novel lipid nanoparticle (LNP) formulation that significantly enhances extra-hepatic delivery of mRNA specifically to lung tissue. This adva... -
Moderna and BioNTech Forge Strategic Partnership to Co-Develop mRNA Therapeutics for Infectious Diseases
Fierce Biotech USA Overview Moderna and BioNTech, leaders in mRNA vaccine technology, have announced a strategic partnership to co-develop novel mRNA-based therapeutics targeting emerging infectious diseases. This collaboration aims to a... -
Alnylam’s ALN-XXX siRNA Therapy Achieves Primary Endpoint in Phase 2 Trial for Rare Inherited Liver Disease
Alnylam Pharmaceuticals Press Release USA Overview Alnylam Pharmaceuticals announced positive topline results from its Phase 2 study of ALN-XXX, an investigational siRNA therapeutic for a rare inherited liver disease. The trial successfu... -
AlphaFold-Derived Optimized Protein Demonstrates Significant Efficacy in Autoimmune Disease Animal Models, Accelerating AI-Driven Protein Therapeutic Design
bioRxiv Unknown Overview A bioRxiv preprint details preclinical development of a novel therapeutic protein with structure predicted and optimized using AlphaFold. This protein showed remarkable efficacy in animal models of autoimmune dis... -
Recursion Pharmaceuticals Initiates Phase 1 Clinical Trial for AI-Designed Cancer Candidate Drug
ClinicalTrials.gov USA Overview Recursion Pharmaceuticals has registered a novel Phase 1 clinical trial (NCTxxxxxxx) for an AI-designed small molecule cancer candidate drug in patients with advanced solid tumors. This trial will evaluate... -
Insilico Medicine’s AI Platform Identifies Novel Fibrosis Target, Accelerating Preclinical Drug Development
BioRender News USA Overview Insilico Medicine announced its AI-driven drug discovery platform successfully identified a novel therapeutic target for specific fibrotic diseases, validated by in vitro experiments. This high-precision predi... -
China’s Guoxiang Shiji to Build Integrated Solid-State Battery Industrial Complex in Shanghai Jiading, Unifying R&D to Mass Production
Gasgoo Express China Overview Guoxiang Shiji's new energy project has been officially settled in Jiading, Shanghai, with plans to build a solid-state battery industrial complex. This comprehensive facility will integrate a headquarters, ... -
Japan’s METI Accelerates Solid-State Battery Commercialization by 2030, Aims to Triple Battery Sales to Meet AI Data Center Demand
BigGo Finance Japan Overview Japan's Ministry of Economy, Trade and Industry (METI) has unveiled a new strategy to triple sales by Japanese battery companies by 2035. The plan includes accelerating the full-scale commercialization of sol...
